Brian Adams - 04 Sep 2026 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Reporting relationship: Chief Legal Officer
Issuer ticker: KYMR
Reported as of: 04 Sep 2026
Net transaction value: -$744,297
SEC form: 4
Accepted by SEC: 04 Sep 2026, 18:00:03 UTC
Prior SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Bruce Jacobs, as Attorney-in-Fact

Filing notes and source

Key filing fact

Brian Adams filed Form 4 for Kymera Therapeutics, Inc. (KYMR) on 04 Sep 2026.

Key facts

This page summarizes Brian Adams's Form 4 filing for Kymera Therapeutics, Inc. (KYMR).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Sep 2026, 18:00.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: -$744,297.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636994 Primary reporting owner

Adams Brian

Relationship: Chief Legal Officer
Address: 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Signature date: 04 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KYMR transaction

Common Stock

Sale

Transaction value: -$139,700
Shares: -1,209
Change %: -2.1%
Price: $115.55
Shares after: 55,416
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F2

KYMR transaction

Common Stock

Sale

Transaction value: -$353,350
Shares: -3,025
Change %: -5.5%
Price: $116.81
Shares after: 52,391
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F3

KYMR transaction

Common Stock

Sale

Transaction value: -$251,247
Shares: -2,137
Change %: -4.1%
Price: $117.57
Shares after: 50,254
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.